Caroline Hastings, MD

Dr. Caroline Hastings is a Professor of Pediatrics and is specialty boarded in Pediatric Hematology Oncology. She has been at Children's Hospital Oakland and now UCSF since completion of her training in 1992. Her longevity in the group has allowed for personal and professional growth and development of long-term relationships with her patients. She is currently focused in the NeuroOncology program as well as leading clinical trials and serving as an international consultant for rare lysosomal diseases including Neimann-Pick Type C, Gangliosidoses and Acid Sphingomyelinase deficiency. She also has several roles related to graduate medical education including serving as the Fellowship Director in Pediatric Hematology Oncology at Children's Hospital Oakland since 1996, as well as serving as the chair for the Graduate Medical Education committee in which she works with the program directors in ensuring regulatory compliance and quality training.
Dr. Hastings serves as the President of the American Society of Pediatric Hematology Oncology and in this role is very active in addressing workforce issues for faculty and trainees, advocacy, and issues related to the practice of the specialty and continuing education.
Education
6/1992 - Pediatric Hematology Oncology Fellowship, Children's Hospital Oakland
06/1989 - Pediatric residency, Children's Hospital Oakland
MD, 6/1986 - Medicine, University fo California, Davis

  1. Hastings C, Borinstein SC, Bergsagel DJ, Hagstrom JN, Hooker R, Nugent DJ, Hudspeth M, American Society of Pediatric Hematology Oncology Workforce Publication Workgroup. The American Society of Pediatric Hematology Oncology workforce, productivity, and fellowship assessment: Current state of the workforce. Pediatric blood & cancer 2023. PMID: 36722007


  2. Hastings C, Liu B, Hurst B, Cox GF, Hrynkow S. Intravenous 2-hydroxypropyl-�-cyclodextrin (Trappsol� Cyclo�) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a Molecular genetics and metabolism 2022. PMID: 36279795


  3. Andrews JP, Coleman C, Hastings C, Sun PP. Oncogenic NTRK fusion in congenital spinal cord glioblastoma: sequencing directs treatment. 2021. PMID: 34895532


  4. Hastings C, Chen Y, Devidas M, Ritchey AK, Winick NJ, Carroll WL, Hunger SP, Wood BL, Marcus RB, Barredo JC. Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALL02P2. 2021. PMID: 34302704


  5. Agrawal AK, Michlitsch J, Golden C, Hastings CA, Raphael R, Feusner JH. Nelarabine in Pediatric and Young Adult T-Cell Acute Lymphoblastic Leukemia-Clearly Beneficial? 2021. PMID: 33444071


  6. Lew G, Chen Y, Lu X, Rheingold SR, Whitlock JA, Devidas M, Hastings CA, Winick NJ, Carroll WL, Wood BL, Borowitz MJ, Pulsipher MA, Hunger SP. Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. 2021. PMID: 32001530


  7. Hastings C, Vieira C, Liu B, Bascon C, Gao C, Wang RY, Casey A, Hrynkow S. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis. 2019. PMID: 31639011


  8. Hastings C. The ASPHO 2019 distinguished career award goes to Dr. Elliott P. Vichinsky. 2019. PMID: 30825260


  9. Barredo JC, Hastings C, Lu X, Devidas M, Chen Y, Armstrong D, Winick N, Wood BL, Yanofsky R, Loh M, Gastier-Foster JM, Jorstad DT, Marcus R, Ritchey K, Carrol WL, Hunger SP. Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatric blood & cancer 2017. PMID: 29286562


  10. Seibel NL, Steinherz PG, Sather HN, Nachman JB, Delaat C, Ettinger LJ, Freyer DR, Mattano LA, Hastings CA, Rubin CM, Bertolone K, Franklin JL, Heerema NA, Mitchell TL, Pyesmany AF, La MK, Edens C, Gaynon PS. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. 2007. PMID: 18039957